Arrieta O, Catalan R, Guzman-Vazquez S, Barron F, et al. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer 2020;20:829.
PMID: 32873256